Zimmer Builds up Biologics Portfolio with ETEX Acquisition

Zimmer Holdings, Inc. has acquired ETEX Holdings, Inc. in a deal the details of which have not been disclosed at this time.


With the acquisition, Zimmer’s Biologics portfolio will be enhanced by the addition of ETEX’s Beta-bsm™ (Injectable), CarriGen®, EquivaBone® (including DBM), and Gamma-bsm™ (Putty) bone void filler products.

Company comments

for ETEX

“Since 1989, ETEX has been focused on Dosuk Lee’s vision of providing clinical solutions that advance the orthopaedic standard of care. His breakthrough technology in biomimetic calcium phosphate, which mimics the chemical and structural features of human bone, promotes natural bone regeneration that positively impacts patients’ lives,” said Stephen R. La Neve, ETEX President and Chief Executive Officer. “Zimmer’s long history, dedication and focus in the orthopaedic market is a perfect complement to our technology and dramatically expands our ability to reach a broader array of clinicians.”

for Zimmer

“Zimmer is committed to developing the most comprehensive range of biologic therapies for patients suffering from musculoskeletal joint disease, from early intervention solutions like Gel-One®* Cross-linked Hyaluronate and joint preservation solutions like Zimmer Knee Creations™ Subchondroplasty® Procedure, along with Zimmer’s Chondrofix® Osteochondral Allograft and Denovo® NT Natural Tissue Graft personalized cartilage solutions. ETEX’s innovative bone substitute material products add more depth to a growing portfolio of solutions for the early stages of joint disease,” said Joseph A. Cucolo, President, Zimmer Americas.

*Gel-One is a registered trademark of Seikagaku Corporation.

Source: Zimmer Holdings, Inc., PR Newswire

Share your thoughts

Your email address will not be published. Required fields are marked *